[HTML][HTML] Therapeutic targeting of acute myeloid leukemia by gemtuzumab ozogamicin
M Gottardi, G Simonetti, A Sperotto, D Nappi… - Cancers, 2021 - mdpi.com
Simple Summary Gemtuzumab Ozogamicin (GO) is a drug approved for the treatment of
acute myeloid leukemia (AML). It targets leukemic cells that express the CD33 molecule on …
acute myeloid leukemia (AML). It targets leukemic cells that express the CD33 molecule on …
Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin
M Gottardi, G Simonetti, A Sperotto, D Nappi… - …, 2021 - search.proquest.com
Acute myeloid leukemia (AML) is a complex hematological malignancy characterized by
genetic and clinical heterogeneity and high mortality. Despite the recent introduction of …
genetic and clinical heterogeneity and high mortality. Despite the recent introduction of …
[HTML][HTML] Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin
M Gottardi, G Simonetti, A Sperotto, D Nappi… - Cancers, 2021 - ncbi.nlm.nih.gov
Acute myeloid leukemia (AML) is a complex hematological malignancy characterized by
genetic and clinical heterogeneity and high mortality. Despite the recent introduction of …
genetic and clinical heterogeneity and high mortality. Despite the recent introduction of …
Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin
M Gottardi, G Simonetti, A Sperotto, D Nappi… - …, 2021 - pubmed.ncbi.nlm.nih.gov
Acute myeloid leukemia (AML) is a complex hematological malignancy characterized by
genetic and clinical heterogeneity and high mortality. Despite the recent introduction of …
genetic and clinical heterogeneity and high mortality. Despite the recent introduction of …
Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin.
M Gottardi, G Simonetti, A Sperotto, D Nappi, A Padella… - Cancers, 2021 - europepmc.org
Acute myeloid leukemia (AML) is a complex hematological malignancy characterized by
genetic and clinical heterogeneity and high mortality. Despite the recent introduction of …
genetic and clinical heterogeneity and high mortality. Despite the recent introduction of …
Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin.
M Gottardi, G Simonetti, A Sperotto, D Nappi… - …, 2021 - search.ebscohost.com
Abstract Simple Summary: Gemtuzumab Ozogamicin (GO) is a drug approved for the
treatment of acute myeloid leukemia (AML). It targets leukemic cells that express the CD33 …
treatment of acute myeloid leukemia (AML). It targets leukemic cells that express the CD33 …
Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin
M Gottardi, G Simonetti, A Sperotto, D Nappi… - CANCERS, 2021 - cris.unibo.it
Abstract Simple Summary Gemtuzumab Ozogamicin (GO) is a drug approved for the
treatment of acute myeloid leukemia (AML). It targets leukemic cells that express the CD33 …
treatment of acute myeloid leukemia (AML). It targets leukemic cells that express the CD33 …
[PDF][PDF] Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin. Cancers 2021, 13, 4566
M Gottardi, G Simonetti, A Sperotto, D Nappi… - 2021 - core.ac.uk
Acute myeloid leukemia (AML) is a complex hematological malignancy characterized by
genetic and clinical heterogeneity and high mortality. Despite the recent introduction of …
genetic and clinical heterogeneity and high mortality. Despite the recent introduction of …
Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin.
M Gottardi, G Simonetti, A Sperotto, D Nappi, A Padella… - Cancers, 2021 - europepmc.org
Acute myeloid leukemia (AML) is a complex hematological malignancy characterized by
genetic and clinical heterogeneity and high mortality. Despite the recent introduction of …
genetic and clinical heterogeneity and high mortality. Despite the recent introduction of …